# Clarapath

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clarapath

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.clarapath.com
- Total disclosed funding: $41M
- Latest round: Series B (Jul 25, 2024)
- Investors on record: 8

## About

Based in the US, Clarapath Inc. is a healthcare technology company focused on laboratory automation, enhancing efficiency in slide preparation for histotechnicians through innovative robotic solutions.Clarapath Inc. is a company that specializes in laboratory automation services. Founded in 2014 in the United States, it has secured its position through a Series B funding round in July 2024, raising USD 24.73 mn led by Northwell Holdings, with participation from CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures. Eric Feinstein is the current CEO, guiding the company's operations as it pursues growth in the healthcare robotics sector.Clarapath specializes in laboratory automation with its flagship product, the SectionStar, designed to optimize slide preparation for histotechnicians. This system automates the sectioning of tissue specimens, capable of processing 72 blocks or 200 slides per session, with customizable sectioning thickness from 3 to 10 microns. It utilizes custom-engineered robotics integrated with various subsystems to enhance precision and reduce contamination, catering to histology laboratories in clinical settings, research facilities, and veterinary clinics across North America, Europe, and Asia.Clarapath generates revenue through sales of its SectionStar systems and related software solutions, involving direct sales to laboratory clients. These transactions comprise one-time hardware purchases alongside ongoing subscription fees for software updates and support services. The pricing includes an initial investment for equipment, along with maintenance and software licenses, aiming to form long-term partnerships with healthcare professionals and institutions.In July 2024, Clarapath Inc. raised USD 24.73 mn in Series B funding to support its product commercialization and enhance research and development efforts. The company is focusing on expanding its market reach internationally, specifically targeting Europe and Asia for growth. The recent funding will enable the development of new product lines aimed at further advancing laboratory automation capabilities.

## Funding rounds

- Series B, Jul 25, 2024, $25M — Mayo Clinic, Northwell Holdings, CU Healthcare Innovation Fund, Ochsner Ventures
- Series B, Nov 17, 2021, $16M — White Plains Hospital Medical Center and Subsidiaries, Northwell Holdings, P5 Health Ventures, Epiphron Capital, The 4100 Group

## Investors

- White Plains Hospital Medical Center and Subsidiaries — Series B
- Northwell Holdings (https://capitalatlas.ai/funds/northwell-holdings) — Series B
- P5 Health Ventures (https://capitalatlas.ai/funds/p5-health-ventures) — Series B
- Epiphron Capital — Series B
- The 4100 Group — Series B
- Mayo Clinic — Series B
- CU Healthcare Innovation Fund (https://capitalatlas.ai/funds/cu-healthcare-innovation-fund) — Series B
- Ochsner Ventures (https://capitalatlas.ai/funds/ochsner-ventures) — Series B